S&P 500   3,671.47 (+0.07%)
DOW   29,986.22 (+0.34%)
QQQ   304.26 (+0.13%)
AAPL   123.41 (+0.27%)
MSFT   215.04 (-0.15%)
FB   285.93 (-0.55%)
GOOGL   1,837.45 (+0.68%)
AMZN   3,225.73 (+0.69%)
TSLA   587.76 (+3.33%)
NVDA   544.75 (+0.55%)
BABA   263.40 (+0.80%)
CGC   27.79 (-1.38%)
GE   10.44 (+0.10%)
MU   69.66 (+0.80%)
AMD   93.28 (-0.49%)
T   29.02 (-0.24%)
NIO   46.30 (-3.50%)
F   9.26 (+0.65%)
ACB   10.69 (-2.37%)
NFLX   508.02 (+0.92%)
BA   230.18 (+2.83%)
GILD   61.15 (+0.03%)
DIS   152.55 (-0.69%)
S&P 500   3,671.47 (+0.07%)
DOW   29,986.22 (+0.34%)
QQQ   304.26 (+0.13%)
AAPL   123.41 (+0.27%)
MSFT   215.04 (-0.15%)
FB   285.93 (-0.55%)
GOOGL   1,837.45 (+0.68%)
AMZN   3,225.73 (+0.69%)
TSLA   587.76 (+3.33%)
NVDA   544.75 (+0.55%)
BABA   263.40 (+0.80%)
CGC   27.79 (-1.38%)
GE   10.44 (+0.10%)
MU   69.66 (+0.80%)
AMD   93.28 (-0.49%)
T   29.02 (-0.24%)
NIO   46.30 (-3.50%)
F   9.26 (+0.65%)
ACB   10.69 (-2.37%)
NFLX   508.02 (+0.92%)
BA   230.18 (+2.83%)
GILD   61.15 (+0.03%)
DIS   152.55 (-0.69%)
S&P 500   3,671.47 (+0.07%)
DOW   29,986.22 (+0.34%)
QQQ   304.26 (+0.13%)
AAPL   123.41 (+0.27%)
MSFT   215.04 (-0.15%)
FB   285.93 (-0.55%)
GOOGL   1,837.45 (+0.68%)
AMZN   3,225.73 (+0.69%)
TSLA   587.76 (+3.33%)
NVDA   544.75 (+0.55%)
BABA   263.40 (+0.80%)
CGC   27.79 (-1.38%)
GE   10.44 (+0.10%)
MU   69.66 (+0.80%)
AMD   93.28 (-0.49%)
T   29.02 (-0.24%)
NIO   46.30 (-3.50%)
F   9.26 (+0.65%)
ACB   10.69 (-2.37%)
NFLX   508.02 (+0.92%)
BA   230.18 (+2.83%)
GILD   61.15 (+0.03%)
DIS   152.55 (-0.69%)
S&P 500   3,671.47 (+0.07%)
DOW   29,986.22 (+0.34%)
QQQ   304.26 (+0.13%)
AAPL   123.41 (+0.27%)
MSFT   215.04 (-0.15%)
FB   285.93 (-0.55%)
GOOGL   1,837.45 (+0.68%)
AMZN   3,225.73 (+0.69%)
TSLA   587.76 (+3.33%)
NVDA   544.75 (+0.55%)
BABA   263.40 (+0.80%)
CGC   27.79 (-1.38%)
GE   10.44 (+0.10%)
MU   69.66 (+0.80%)
AMD   93.28 (-0.49%)
T   29.02 (-0.24%)
NIO   46.30 (-3.50%)
F   9.26 (+0.65%)
ACB   10.69 (-2.37%)
NFLX   508.02 (+0.92%)
BA   230.18 (+2.83%)
GILD   61.15 (+0.03%)
DIS   152.55 (-0.69%)
Log in
NYSE:TFX

Teleflex Stock Forecast, Price & News

$380.38
-0.09 (-0.02 %)
(As of 12/2/2020 12:00 AM ET)
Add
Compare
Today's Range
$376.88
Now: $380.38
$384.05
50-Day Range
$318.23
MA: $358.29
$382.75
52-Week Range
$221.27
Now: $380.38
$409.27
Volume243,887 shs
Average Volume254,720 shs
Market Capitalization$17.71 billion
P/E Ratio37.44
Dividend Yield0.36%
Beta1.03
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products consist of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology product comprises the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management for patients in the hospital and individuals in the home care markets. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was founded in 1943 and is headquartered in Wayne, Pennsylvania.
Teleflex logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.2Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.78 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP87936910
Phone610-225-6800
Employees14,400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.60 billion
Cash Flow$16.89 per share
Book Value$64.35 per share

Profitability

Net Income$461.47 million

Miscellaneous

Market Cap$17.71 billion
Next Earnings Date2/18/2021 (Estimated)
OptionableOptionable
$380.38
-0.09 (-0.02 %)
(As of 12/2/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TFX News and Ratings via Email

Sign-up to receive the latest news and ratings for TFX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Teleflex (NYSE:TFX) Frequently Asked Questions

How has Teleflex's stock price been impacted by COVID-19?

Teleflex's stock was trading at $342.08 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TFX stock has increased by 11.2% and is now trading at $380.38.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Teleflex?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teleflex in the last year. There are currently 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Teleflex
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Teleflex?

Wall Street analysts have given Teleflex a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Teleflex wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Teleflex's next earnings date?

Teleflex is scheduled to release its next quarterly earnings announcement on Thursday, February 18th 2021.
View our earnings forecast for Teleflex
.

How were Teleflex's earnings last quarter?

Teleflex Incorporated (NYSE:TFX) issued its quarterly earnings results on Thursday, October, 29th. The medical technology company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.24 by $0.53. The medical technology company had revenue of $628.30 million for the quarter, compared to the consensus estimate of $618.18 million. Teleflex had a return on equity of 17.15% and a net margin of 18.99%. The company's quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.97 EPS.
View Teleflex's earnings history
.

How often does Teleflex pay dividends? What is the dividend yield for Teleflex?

Teleflex declared a quarterly dividend on Thursday, October 29th. Stockholders of record on Sunday, November 15th will be given a dividend of $0.34 per share on Tuesday, December 15th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.36%. The ex-dividend date of this dividend is Thursday, November 12th.
View Teleflex's dividend history
.

What price target have analysts set for TFX?

11 analysts have issued 1-year price targets for Teleflex's stock. Their forecasts range from $275.00 to $440.00. On average, they expect Teleflex's share price to reach $388.27 in the next year. This suggests a possible upside of 2.1% from the stock's current price.
View analysts' price targets for Teleflex
.

Who are some of Teleflex's key competitors?

What other stocks do shareholders of Teleflex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teleflex investors own include NVIDIA (NVDA), AbbVie (ABBV), Johnson & Johnson (JNJ), Alibaba Group (BABA), Lam Research (LRCX), ServiceNow (NOW), QUALCOMM (QCOM), Advanced Micro Devices (AMD), salesforce.com (CRM) and Cisco Systems (CSCO).

Who are Teleflex's key executives?

Teleflex's management team includes the following people:
  • Mr. Liam J. Kelly, Chairman, Pres & CEO (Age 53, Pay $2.33M)
  • Mr. Thomas E. Powell, Exec. VP & CFO (Age 58, Pay $1.2M)
  • Mr. James J. Leyden, Corp. VP, Gen. Counsel & Sec. (Age 53, Pay $591.92k)
  • Mr. Cameron P. Hicks, Corp. VP of HR & Communications (Age 55, Pay $557.86k)
  • Mr. John R. Deren, VP & Chief Accounting Officer
  • Mr. Timothy F. Duffy, VP & Chief Information Officer
  • Mr. Jacob P. Elguicze, Treasurer & VP of Investor Relations (Age 47)
  • Ms. Gwen Chapman, Chief Compliance Officer & Corp. VP (Age 45)
  • Ms. Gwendolyn Ann Watanabe, Corp. VP of Global Corp. Devel., Strategy and Strategic Partnerships (Age 49)
  • Mr. David R. Amerson, Pres & GM of Interventional Urology

What is Teleflex's stock symbol?

Teleflex trades on the New York Stock Exchange (NYSE) under the ticker symbol "TFX."

Who are Teleflex's major shareholders?

Teleflex's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (10.56%), State Street Corp (4.16%), William Blair Investment Management LLC (1.13%), Principal Financial Group Inc. (0.61%), Charles Schwab Investment Management Inc. (0.50%) and Villere ST Denis J & Co. LLC (0.46%). Company insiders that own Teleflex stock include Benson Smith, Cameron P Hicks, James J Leyden, John C Heinmiller, John Deren, Karen Boylan, Stephen K MD Klasko, Stuart A Randle and Thomas E Powell.
View institutional ownership trends for Teleflex
.

Which institutional investors are selling Teleflex stock?

TFX stock was sold by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, State Street Corp, Villere ST Denis J & Co. LLC, Scout Investments Inc., New York State Common Retirement Fund, Daiwa Securities Group Inc., Rothschild & Co. Asset Management US Inc., and Montag & Caldwell LLC. Company insiders that have sold Teleflex company stock in the last year include Cameron P Hicks, James J Leyden, John Deren, and Stephen K MD Klasko.
View insider buying and selling activity for Teleflex
.

Which institutional investors are buying Teleflex stock?

TFX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Ceredex Value Advisors LLC, Natixis, Cubist Systematic Strategies LLC, Polar Capital LLP, Polar Capital LLP, Great West Life Assurance Co. Can, and Squarepoint Ops LLC.
View insider buying and selling activity for Teleflex
.

How do I buy shares of Teleflex?

Shares of TFX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Teleflex's stock price today?

One share of TFX stock can currently be purchased for approximately $380.38.

How big of a company is Teleflex?

Teleflex has a market capitalization of $17.71 billion and generates $2.60 billion in revenue each year. The medical technology company earns $461.47 million in net income (profit) each year or $11.15 on an earnings per share basis. Teleflex employs 14,400 workers across the globe.

What is Teleflex's official website?

The official website for Teleflex is www.teleflex.com.

How can I contact Teleflex?

Teleflex's mailing address is 550 E SWEDESFORD RD, WAYNE PA, 19087. The medical technology company can be reached via phone at 610-225-6800 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.